Blinatumomab @ ASH 2019
Zusätzliche Evidenz für die Effektivität von Blinatumomab in adulter und pädiatrischer B-ALL.
Zusätzliche Evidenz für die Effektivität von Blinatumomab in adulter und pädiatrischer B-ALL.
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties